Urine-derived stem cells as innovative platform for drug testing and disease modelling
Posted: 20 July 2018 | Audrey Ncube, James Adjaye (Heinrich-Heine-University), Lisa Nguyen, Lucas-Sebastian Spitzhorn, Martina Bohndorf, Shaifur Rahman, Wasco Wruck (Heinrich-Heine-University) | No comments yet
Kidneys are crucial for filtration of drugs and toxins and their proper function is essential for overall health. Unfortunately, due to disease and improper function, kidney transplantation or dialysis are necessary for millions of patients annually all over the world.1,2
CLINICIANS face several hurdles, such as limited organ donors and high financial demands, during the course of administering the necessary treatment options.3 The kidney metabolises drugs via cytochrome P450 and other protein systems.4 The increasing prevalence of acute kidney injury (AKI) is associated with medical and economic burdens.5 AKI, of which 19-26% are induced by drugs, can result in chronic kidney disease (CKD),6,7 which increases the probability of developing renal cell carcinoma.8 Nephrotoxicity caused by drugs is an important causative factor in the development of AKI and CKD.9 It causes failure of about 7% of newly developed drugs, thus emphasising that pre-clinical models have to be improved.10
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!